JPS6191137A - 外用薬剤組成物 - Google Patents

外用薬剤組成物

Info

Publication number
JPS6191137A
JPS6191137A JP59213152A JP21315284A JPS6191137A JP S6191137 A JPS6191137 A JP S6191137A JP 59213152 A JP59213152 A JP 59213152A JP 21315284 A JP21315284 A JP 21315284A JP S6191137 A JPS6191137 A JP S6191137A
Authority
JP
Japan
Prior art keywords
drug component
acid
drug
dialkyl phosphate
phosphate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP59213152A
Other languages
English (en)
Japanese (ja)
Other versions
JPH0469129B2 (enExample
Inventor
Kenji Hara
健次 原
Hiromichi Takahashi
広通 高橋
Tetsuro Kamiya
神谷　哲朗
Kaoru Tsujii
辻井　薫
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kao Corp
Original Assignee
Kao Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kao Corp filed Critical Kao Corp
Priority to JP59213152A priority Critical patent/JPS6191137A/ja
Priority to DE8585111872T priority patent/DE3565937D1/de
Priority to EP85111872A priority patent/EP0179277B1/en
Priority to US06/778,226 priority patent/US4686211A/en
Priority to ES547738A priority patent/ES8701683A1/es
Publication of JPS6191137A publication Critical patent/JPS6191137A/ja
Priority to MYPI87000383A priority patent/MY100022A/en
Priority to HK336/91A priority patent/HK33691A/en
Publication of JPH0469129B2 publication Critical patent/JPH0469129B2/ja
Granted legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/08—Esters of oxyacids of phosphorus
    • C07F9/09—Esters of phosphoric acids
    • C07F9/091—Esters of phosphoric acids with hydroxyalkyl compounds with further substituents on alkyl

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP59213152A 1984-10-11 1984-10-11 外用薬剤組成物 Granted JPS6191137A (ja)

Priority Applications (7)

Application Number Priority Date Filing Date Title
JP59213152A JPS6191137A (ja) 1984-10-11 1984-10-11 外用薬剤組成物
DE8585111872T DE3565937D1 (en) 1984-10-11 1985-09-19 Medical composition for external application
EP85111872A EP0179277B1 (en) 1984-10-11 1985-09-19 Medical composition for external application
US06/778,226 US4686211A (en) 1984-10-11 1985-09-20 Medical composition for external application
ES547738A ES8701683A1 (es) 1984-10-11 1985-10-09 Un procedimiento para la preparacion de una composicion terapeutica que contiene un fosfato de dialquilo.
MYPI87000383A MY100022A (en) 1984-10-11 1987-03-26 Medical composition for external application
HK336/91A HK33691A (en) 1984-10-11 1991-05-02 Medical composition for external application

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP59213152A JPS6191137A (ja) 1984-10-11 1984-10-11 外用薬剤組成物

Publications (2)

Publication Number Publication Date
JPS6191137A true JPS6191137A (ja) 1986-05-09
JPH0469129B2 JPH0469129B2 (enExample) 1992-11-05

Family

ID=16634426

Family Applications (1)

Application Number Title Priority Date Filing Date
JP59213152A Granted JPS6191137A (ja) 1984-10-11 1984-10-11 外用薬剤組成物

Country Status (7)

Country Link
US (1) US4686211A (enExample)
EP (1) EP0179277B1 (enExample)
JP (1) JPS6191137A (enExample)
DE (1) DE3565937D1 (enExample)
ES (1) ES8701683A1 (enExample)
HK (1) HK33691A (enExample)
MY (1) MY100022A (enExample)

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH02193909A (ja) * 1988-12-01 1990-07-31 Unilever Nv 局所組成物
JPH02193910A (ja) * 1988-12-01 1990-07-31 Unilever Nv 局所組成物
JPH02200616A (ja) * 1988-12-01 1990-08-08 Unilever Nv 局所組成物
JPH02256606A (ja) * 1988-12-01 1990-10-17 Unilever Nv 局所組成物
JP2004513183A (ja) * 2000-11-14 2004-04-30 バイタル　ヘルス　サイエンシズ　プロプライアタリー　リミティド リン酸誘導体の複合体
US10071030B2 (en) 2010-02-05 2018-09-11 Phosphagenics Limited Carrier comprising non-neutralised tocopheryl phosphate
US10188670B2 (en) 2011-03-15 2019-01-29 Phosphagenics Limited Composition
JP2019043853A (ja) * 2017-08-30 2019-03-22 旭化成株式会社 経皮吸収促進剤、経皮吸収促進助剤、及び経皮製剤
US10973761B2 (en) 2015-12-09 2021-04-13 Phosphagenics Limited Pharmaceutical formulation
US11753435B2 (en) 2016-12-21 2023-09-12 Avecho Biotechnology Limited Process

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH01151516A (ja) * 1987-12-08 1989-06-14 Shionogi & Co Ltd ビタミンｅ配合外用剤
GB8828018D0 (en) * 1988-12-01 1989-01-05 Unilever Plc Topical composition
US4906454A (en) * 1989-02-23 1990-03-06 The Procter & Gamble Company Deodorant compositions containing specific piroctone salts and perfumes
US5262165A (en) * 1992-02-04 1993-11-16 Schering Corporation Transdermal nitroglycerin patch with penetration enhancers
GB9003199D0 (en) * 1990-02-13 1990-04-11 Unilever Plc Topical composition
US5565207A (en) * 1990-09-19 1996-10-15 Pola Kasei Kogyo Kabushiki Kaisha Scalp moisturizer and external skin preparation
GB9101986D0 (en) * 1991-01-30 1991-03-13 Smith & Nephew Pharmaceutical compositions
US5409911A (en) * 1992-09-11 1995-04-25 Merck & Co., Inc. Prostaglandin analog for treating osteoporosis
TW251302B (enExample) * 1992-12-28 1995-07-11 Kao Corp
US5665742A (en) * 1994-05-31 1997-09-09 Kao Corporation Bath medicine composition and its use in inhibiting the generation of body odor
US5543430A (en) * 1994-10-05 1996-08-06 Kaesemeyer; W. H. Method and formulation of stimulating nitric oxide synthesis
US20110196039A9 (en) * 1994-10-05 2011-08-11 Kaesemeyer Wayne H Controlled release arginine formulations
US6239172B1 (en) * 1997-04-10 2001-05-29 Nitrosystems, Inc. Formulations for treating disease and methods of using same
US5968983A (en) * 1994-10-05 1999-10-19 Nitrosystems, Inc Method and formulation for treating vascular disease
US5560913A (en) * 1995-01-27 1996-10-01 The Procter & Gamble Company Pharmaceutical compositions
US6605751B1 (en) * 1997-11-14 2003-08-12 Acrymed Silver-containing compositions, devices and methods for making
WO1999039575A2 (en) * 1998-02-09 1999-08-12 Yissum Research Development Company Of The Hebrew University Of Jerusalem Synergistic biocidal activity of ternary complexes of negatively -charged biocides (component a), transition metal ions (component b), and neutral chelators (component c)
US5972920A (en) * 1998-02-12 1999-10-26 Dermalogix Partners, Inc. Formulation containing a carrier, active ingredient, and surfactant for treating skin disorders
US6121253A (en) * 1998-11-20 2000-09-19 Merck Frosst Canada & Co. Prostaglandin conjugates for treating or preventing bone disease
US6254294B1 (en) * 1999-08-09 2001-07-03 Sigrid G. Muhar Pharmaceutical kit
FR2799369B1 (fr) * 1999-10-08 2001-12-21 Oreal Association d'escine et de sulfate de dextran et son utilisation
DE60028415T2 (de) * 1999-12-30 2007-06-06 Acrymed, Portland Methode und zusammensetzungen für verbesserte abgabevorrichtungen
US7758888B2 (en) * 2000-04-21 2010-07-20 Sol-Gel Technologies Ltd. Composition exhibiting enhanced formulation stability and delivery of topical active ingredients
AUPR549901A0 (en) 2001-06-06 2001-07-12 Vital Health Sciences Pty Ltd Topical formulation containing tocopheryl phosphates
EP1254909A1 (de) * 2001-04-30 2002-11-06 Cognis Iberia, S.L. Phosphorsäureester
MXPA04000654A (es) * 2001-07-27 2004-03-19 Vital Health Sciences Pty Ltd Terapia dermica usando derivados de fosfato de agente de transferencia de electrones.
CA2466536C (en) * 2001-12-13 2012-02-07 Vital Health Sciences Pty Ltd Transdermal transport of compounds
US6833139B1 (en) * 2002-01-09 2004-12-21 Ferndale Laboratories, Inc. Composition and method for the treatment of anorectal disorders
US8486426B2 (en) * 2002-07-29 2013-07-16 Kimberly-Clark Worldwide, Inc. Methods and compositions for treatment of dermal conditions
AU2002950713A0 (en) * 2002-08-09 2002-09-12 Vital Health Sciences Pty Ltd Carrier
WO2004064831A1 (en) * 2003-01-17 2004-08-05 Vital Health Sciences Pty Ltd Compounds having anti-proliferative properties
AU2003901815A0 (en) * 2003-04-15 2003-05-01 Vital Health Sciences Pty Ltd Phosphate derivatives
DE602005025979D1 (de) 2004-03-03 2011-03-03 Vital Health Sciences Pty Ltd Alkaloid-formulierungen
US20050282870A1 (en) * 2004-06-16 2005-12-22 Carter Stephen G Peripherally-acting vasodilators
US8361553B2 (en) 2004-07-30 2013-01-29 Kimberly-Clark Worldwide, Inc. Methods and compositions for metal nanoparticle treated surfaces
NZ592438A (en) 2004-07-30 2012-11-30 Kimberly Clark Co Antimicrobial compositions of silver nanoparticles
CN102783499A (zh) * 2004-07-30 2012-11-21 金伯利-克拉克环球有限公司 抗微生物的装置和组合物
EP1809264B1 (en) * 2004-09-20 2016-04-13 Avent, Inc. Antimicrobial amorphous compositions
JP2008531602A (ja) * 2005-03-03 2008-08-14 バイタル ヘルス サイエンシズ プロプライアタリー リミティド 抗癌特性を有する化合物
CA2611831C (en) * 2005-06-17 2014-09-16 Vital Health Sciences Pty Ltd. A carrier comprising one or more di and/or mono-(electron transfer agent) phosphate derivatives or complexes thereof
CN101277757B (zh) 2005-08-02 2011-11-30 索尔-格尔科技有限公司 非水溶性成分的金属氧化物涂布
BRPI0621081A2 (pt) * 2005-12-23 2011-11-29 Vital Health Sciences Pty Ltd método de modulação de uma ou mais citocinas imuno-reguladoras, uso de um ou mais derivados de fosfato de um ou mais hidróxi cromanos ou complexos dos mesmos, método de inibição de uma resposta inflamatória e/ou de estimulação de uma resposta anti-inflamatória, método de tratamento e/ou de profilaxia de distúbios imunológicos, distúrbios inflamatórios e/ou distúrbios proliferativos celulares, agente imuno-modulador, agente anti-inflamatório ou agente anti-cáncer e um ou mais derivado de fosfato de um ou mais hidróxi cromanos ou complexos dos mesmos
EP2015722B1 (en) * 2006-04-28 2016-11-16 Avent, Inc. Antimicrobial site dressings
BRPI0808160A2 (pt) * 2007-02-01 2014-09-23 Sol Gel Technologies Ltd Processo para revestir um material particulado sólido, insolúvel em água, com um óxido de metal, material particulado revestido, partículas, métodos para tratar uma condição de superfície em um indivíduo, e para prevenir, reduzir, ou eliminar pragas em um local, e, uso de material particulado revestido
JP2010517996A (ja) 2007-02-01 2010-05-27 ソル − ゲル テクノロジーズ リミテッド 過酸化物及びレチノイドを含む局所適用用組成物
JP2010235523A (ja) * 2009-03-31 2010-10-21 Kao Corp 水性毛髪洗浄剤
EP2552486B1 (en) 2010-03-30 2020-08-12 Phosphagenics Limited Transdermal delivery patch
US9687465B2 (en) 2012-11-27 2017-06-27 Sol-Gel Technologies Ltd. Compositions for the treatment of rosacea
CN110869013A (zh) 2017-07-12 2020-03-06 索尔-格尔科技有限公司 包含囊封的维甲酸的组合物

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4046886A (en) * 1975-01-17 1977-09-06 The Procter & Gamble Company Dermatological compositions
US4130667A (en) * 1976-01-12 1978-12-19 The Procter & Gamble Company Dermatological compositions

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH02193909A (ja) * 1988-12-01 1990-07-31 Unilever Nv 局所組成物
JPH02193910A (ja) * 1988-12-01 1990-07-31 Unilever Nv 局所組成物
JPH02200616A (ja) * 1988-12-01 1990-08-08 Unilever Nv 局所組成物
JPH02256606A (ja) * 1988-12-01 1990-10-17 Unilever Nv 局所組成物
JP2004513183A (ja) * 2000-11-14 2004-04-30 バイタル　ヘルス　サイエンシズ　プロプライアタリー　リミティド リン酸誘導体の複合体
US10071030B2 (en) 2010-02-05 2018-09-11 Phosphagenics Limited Carrier comprising non-neutralised tocopheryl phosphate
US10188670B2 (en) 2011-03-15 2019-01-29 Phosphagenics Limited Composition
US10973761B2 (en) 2015-12-09 2021-04-13 Phosphagenics Limited Pharmaceutical formulation
US11753435B2 (en) 2016-12-21 2023-09-12 Avecho Biotechnology Limited Process
JP2019043853A (ja) * 2017-08-30 2019-03-22 旭化成株式会社 経皮吸収促進剤、経皮吸収促進助剤、及び経皮製剤

Also Published As

Publication number Publication date
US4686211A (en) 1987-08-11
EP0179277A1 (en) 1986-04-30
HK33691A (en) 1991-05-10
ES547738A0 (es) 1986-12-01
MY100022A (en) 1989-04-20
JPH0469129B2 (enExample) 1992-11-05
ES8701683A1 (es) 1986-12-01
EP0179277B1 (en) 1988-11-02
DE3565937D1 (en) 1988-12-08

Similar Documents

Publication Publication Date Title
JPS6191137A (ja) 外用薬剤組成物
US4895727A (en) Pharmaceutical vehicles for exhancing penetration and retention in the skin
JP6259454B2 (ja) ジクロフェナク製剤
JPH0225891B2 (enExample)
JPH05178764A (ja) 局所用あるいは経皮用製品におけるジブチルアジペートとイソプロピルミリステートの用途
AU616755B2 (en) Topically applied gold organic complex
JPH0244815B2 (enExample)
JP3091285B2 (ja) 外用消炎鎮痛剤
EP1307231A2 (en) Transdermal drug delivery system
JP2540294B2 (ja) 経皮吸収製剤
JP3313891B2 (ja) 経皮吸収促進剤及び皮膚外用剤
WO1988003799A1 (en) Pharmaceutical vehicles for reducing transdermal flux
JPS61200918A (ja) 外用消炎鎮痛剤
POLEC et al. Protective effect of ascorbic acid, isoascorbic acid and mannitol against tetracycline-induced nephrotoxicity
JP3522832B2 (ja) 経皮吸収促進剤及び皮膚外用剤
JP3313894B2 (ja) 経皮吸収促進剤及び皮膚外用剤
JPS63101317A (ja) 外用剤基剤及びこれを用いる皮膚外用剤
CN111939118B (zh) 一种gsh浓度响应性治疗甲状腺功能亢进的药质体及制备方法
JPH0566930B2 (enExample)
JPH08143474A (ja) 経皮吸収促進剤
Hussain TOPICAL ADMINISTRATION OF GRISEOFULVIN (FORMULATION, SKIN, CONCENTRATION, PENETRATION, PERCUTANEOUS ABSORPTION)
JP3313890B2 (ja) 経皮吸収促進剤及び皮膚外用剤
JPS6172714A (ja) 消炎鎮痛マイクロエマルジヨン剤
JPH02501303A (ja) 全身性薬物を局所投与するための透過促進剤
Hostýnek et al. Role of Copper in Anti-inflammatory Therapy and the Potential for Its Transdermal Application